Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 31 publications
Povorcitinib for hidradenitis suppurativa: the randomized, double-blind, placebo-controlled STOP-HS1 and STOP-HS2 phase 3 trials.
Journal: Nature medicine
Published: May 28, 2026
Correction to: Summary of Research: Efficacy and Safety of Delgocitinib Cream in Adults with Moderate to Severe Chronic Hand Eczema (DELTA 1 and DELTA 2): Results from Multicentre, Randomised, Controlled, Double‑Blind, Phase 3 Trials.
Journal: American journal of clinical dermatology
Published: November 01, 2025
Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in patients with alopecia areata: efficacy and safety results of a phase II, multicentre, randomized, double-blinded, placebo-controlled trial.
Journal: The British journal of dermatology
Published: September 24, 2025
Expert Recommendations for the Diagnosis and Management of Chronic Hand Eczema in the United States.
Expert Recommendations for the Diagnosis and Management of Chronic Hand Eczema in the United States.
Journal: American journal of clinical dermatology
Published: August 29, 2025
Efficacy and safety of rocatinlimab for the treatment of moderate-to-severe atopic dermatitis in ROCKET-IGNITE and ROCKET-HORIZON: two global, double-blind, placebo-controlled, randomised phase 3 clinical trials.
Journal: Lancet (London, England)
Published: August 08, 2025
A longitudinal atlas of human psoriatic skin reveals the mechanisms of anti-IL-23 therapy in disrupting the type 17 inflammatory circuit.
Journal: Immunity
Published: August 07, 2025
Efficacy and Safety of Risankizumab in Genital or Scalp Psoriasis in the UnlIMMited Phase 4 Randomized Clinical Trial at Week 16.
Journal: Dermatology and therapy
Published: July 25, 2025
Summary of Research: Efficacy and Safety of Delgocitinib Cream in Adults with Moderate to Severe Chronic Hand Eczema (DELTA 1 and DELTA 2): Results from Multicentre, Randomised, Controlled, Double-Blind, Phase 3 Trials.
Journal: American journal of clinical dermatology
Published: July 23, 2025
Once-daily oral icotrokinra versus placebo and once-daily oral deucravacitinib in participants with moderate-to-severe plaque psoriasis (ICONIC-ADVANCE 1 & 2): two phase 3, randomised, placebo-controlled and active-comparator-controlled trials.
Journal: Lancet (London, England)
Published: July 08, 2025
Exploring Two New, Validated Disease-Specific Outcome Measures to Assess Severity of Chronic Hand Eczema: Investigator Global Assessment of Chronic Hand Eczema (IGA-CHE) and Hand Eczema Symptom Diary (HESD)-A Podcast.
Journal: Dermatology and therapy
Published: April 08, 2025
A randomized phase 2 clinical trial to treat moderate-to-severe plaque psoriasis patients with high-induction dosing of risankizumab.
Journal: Nature communications
Published: March 24, 2025
Health-Related Quality of Life in Chronic Hand Eczema in a Phase 2b Trial of Delgocitinib Cream.
Journal: Dermatology and therapy
Published: February 11, 2025
Last Updated: 09/26/2026